Study Highlights:
- Cooling resuscitated cardiac arrest patients to lower body temperatures may be associated with a better chance of survival and greater functional ability after recovery.
- Four times as many patients survived cardiac arrest without serious cognitive impairment six months after being cooled to 89.6F/32C compared to those who were cooled to 93.2F/34C.
- Larger studies are needed to determine whether the improved outcome is related to the decreased temperature.
LOS ANGELES, Nov. 6, 2012 (GLOBE NEWSWIRE) -- Cooling patients resuscitated after sudden cardiac arrest to lower body temperatures may be associated with increased survival and better functional ability, according to late-breaking clinical trial research presented at the American Heart Association's Scientific Sessions 2012.
The full manuscript for Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Hospital Cardiac Arrest, is published in Circulation, a journal of the American Heart Association.
In the study of 36 people in Madrid, Spain, researchers found that 44 percent of patients who underwent therapeutic cooling to 32C (89.6F) after cardiac arrest survived without severe brain dysfunction six months after treatment. That compared to 11 percent of those cooled to 34C (93.2F).
Researchers defined dysfunction as the inability to perform the normal tasks of everyday living, including bathing, dressing and walking.
Each year in the United States, about 382,800 people suffer cardiac arrest outside of a hospital, according to the American Heart Association. The life-threatening condition occurs when the heart suddenly stops functioning. Immediate CPR and emergency medical care must be provided within minutes to restore a regular rhythm - or the person will not survive.
Once a normal heartbeat is restored, treatment for comatose patients includes therapeutic cooling to decrease the body's oxygen requirements, which can help prevent brain damage associated with the cardiac arrest. American Heart Association and International Liaison Committee on Resuscitation (ILCOR) recommendations are to cool body temperature to 32C-34C, but the optimal temperature within this range is unclear.
"Although the results suggest a better outcome with lower levels of target temperature, they should be interpreted with caution," said Esteban Lopez-de-Sa, M.D., lead researcher and head of the Cardiac Critical Care Unit and Clinical Cardiology at La Paz University Hospital in Madrid, Spain. "They may be due to multiple factors other than the effect of lower target temperature."
The benefits were observed in patients whose initial detected rhythm was shockable, he said.
Thirty-six patients with out-of-hospital cardiac arrest participated in the single-center trial, from March 2008-August 2011. Their average age was 64, 89 percent were male, and all were white.
Researchers randomly assigned patients to receive therapeutic cooling to either 32C or 34C for 24 hours, followed by gradual rewarming for 12-24 hours. Patients were cooled internally with intravenous cold saline followed by an internal catheter and temperature management system inserted directly into the main vein from the lower body to the heart.
"Since extremely low temperatures below 30C are associated with complications, it's critical to know the optimal level of cooling" Lopez-de-Sa; said. "The aim of the study was to provide initial information for future research about whether controlling hypothermia levels can improve outcome."
Co-authors are Juan R. Rey, M.D.; Eduardo Armada, M.D.; Pablo Salinas, M.D.; Ana Viana, M.D.; Sandra Espinosa-Garcia, M.D.; Mercedes Martinez-Moreno, M.D.; Ervigio Corral, M.D.; and Jose Lopez-Sendon, M.D., Ph.D.
Disclosures are here http://newsroom.heart.org/pr/aha/document/DISCLOSURES.pdf
La Paz University Hospital funded the study.
Follow news from the American Heart Association's Scientific Sessions 2012 via Twitter: @HeartNews.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
Note: The Hypothermia in OCHS presentation is 4:29 p.m. PT, Tuesday, Nov. 6 in Petree Hall D.
The American Heart Association logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9940
For Media Inquiries:
AHA News Media in Dallas: (214) 706-1173
AHA News Media Office, Nov. 3-7,
at the Los Angeles Convention Center: (213) 743-6205
For Public Inquiries: (800) AHA-USA1 (242-8721)